Omega-3 supplements did not significantly reduce major heart disease events overall, but they lowered heart attack risk by 28% in a large U.S. trial. According to research reviewed by Gram, the 1 gram daily dose also reduced autoimmune disease by 18%, while showing no effect on cancer or overall death rates.
A large U.S. clinical trial followed more than 25,000 adults for about five years to test whether daily omega-3 fish oil supplements could prevent heart disease and cancer. Gram Research analysis of the full results found that the supplements did not significantly lower the rate of major heart events overall, which was the trial’s main goal. However, they were linked to a 28% lower rate of heart attacks and a 50% lower rate of fatal heart attacks, although that second estimate was less certain. Participants also had fewer autoimmune diseases, while cancer rates and deaths from any cause were not affected. The possible benefits appeared larger for people who eat little fish. Researchers say routine use by healthy adults is not supported, though people who rarely eat fish may want to talk with a doctor.
Key Statistics
A 2026 analysis of the VITAL trial, which followed 25,871 U.S. adults for a median of 5.3 years, found that daily omega-3 supplements lowered total heart attacks by 28% compared with placebo.
In the same VITAL analysis, omega-3 supplementation was linked to an 18% lower risk of autoimmune disease but did not significantly reduce total cancer incidence or all-cause mortality.
The 2026 VITAL results showed no statistically reliable reduction in major cardiovascular events among 25,871 generally healthy adults, with a hazard ratio of 0.92.
The Quick Take
- What they studied: Whether taking a daily omega-3 fish oil supplement helps generally healthy people avoid heart disease, cancer, and other illnesses over several years.
- Who participated: 25,871 generally healthy U.S. adults: men aged 50 and older and women aged 55 and older. They were not selected for high heart risk and were followed for a median of 5.3 years.
- Key finding: The main goal, reducing major heart events as a group, was not met. However, heart attacks were about 28% less likely in the supplement group (a hazard ratio of 0.72, which compares how often an event happened in each group). Total major heart events were only 8% lower, a difference that could be due to chance.
- What it means for you: Daily omega-3 pills are not recommended for healthy adults to prevent chronic disease in general. People who eat little fish may benefit more, so it makes sense to discuss supplements with a doctor before starting.
The Research Details
The VITamin D and OmegA-3 TriaL, called VITAL, was a nationwide study in which participants were assigned by chance to one of four groups. The trial was a 2 by 2 factorial design, which means it tested two things at once: omega-3 fatty acids and vitamin D3. This summary focuses on the omega-3 part, where participants took 1 gram of marine omega-3s per day or a placebo, which is a pill that looks identical but contains no active ingredient.
Neither the participants nor the researchers knew who was getting which pill, a method called double-blinding that helps prevent bias. Because the groups were formed by chance, they were expected to be similar in age, health, and lifestyle at the start. The researchers then tracked heart attacks, heart procedures, heart failure hospital stays, cancer, autoimmune diseases, and deaths over a median of 5.3 years.
The paper also reports ancillary studies, which are smaller follow-up analyses of specific outcomes such as heart failure, irregular heartbeat (atrial fibrillation), and autoimmune conditions. Some results come from these side analyses, so they carry more uncertainty than the main trial outcomes.
A randomized, placebo-controlled design is the strongest way to test whether a supplement causes a change in health. Because participants were chosen by chance and the pills looked the same, differences between the groups are more likely to come from the supplement itself rather than from lifestyle or other hidden factors. The large size and long follow-up also allowed the researchers to detect events that happen less often, such as fatal heart attacks.
VITAL is one of the largest trials of its kind, and the authors describe it as the only large-scale randomized trial of marine omega-3s for preventing heart disease and cancer in the general population. Its design is a major strength. However, several outcomes were analyzed in multiple ways, and some results came from smaller side studies. Findings from these subgroup and side analyses should be viewed as useful clues rather than firm conclusions until other studies confirm them.
What the Results Show
The main question was whether omega-3 supplements could lower the rate of major cardiovascular events, which include heart attacks, strokes, and related problems requiring treatment. They did not produce a statistically reliable reduction in this combined outcome. The hazard ratio was 0.92, meaning the supplement group had about 8% fewer events, but the range of possible results included no effect at all.
When the researchers looked at specific heart outcomes, the picture changed. Total heart attacks were 28% lower in the supplement group (hazard ratio 0.72, with a range of 0.59 to 0.90). Fatal heart attacks were about 50% lower (hazard ratio 0.50), though the range of estimates was wide, from 0.26 to 0.97, so this finding is less certain. Procedures to open blocked heart arteries, called percutaneous coronary interventions, were 22% lower, and repeat hospital stays for heart failure were 14% lower.
The supplement did not appear to change the risk of atrial fibrillation, a common irregular heartbeat. Total cancer rates, the risk of specific cancers, and overall deaths from any cause were also not significantly reduced.
The researchers also found that the effects varied between groups. Benefits appeared larger in Black participants and in people who ate less fish or had more cardiovascular risk factors. Results also differed somewhat between women and men. These differences are worth noting, but they came from subgroup analyses and should be confirmed in future research.
The most notable secondary finding was a lower risk of autoimmune disease, conditions in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis. Confirmed and probable cases together were about 18% lower in the supplement group (hazard ratio 0.82, with a range of 0.68 to 0.99). This result is intriguing because omega-3 fats are known to influence inflammation, which is involved in many immune conditions. Still, it came from an outcome that was not the study’s main target, so it should be seen as a promising lead rather than settled proof.
Earlier research on fish oil and omega-3 supplements has produced mixed results, with some studies showing heart benefits and others showing little effect. The VITAL authors describe their trial as one of the few large randomized studies of this kind in a general population, which makes it an important addition to the evidence. Its findings fit with the idea that omega-3s may help specific heart outcomes more than overall disease prevention, but they do not settle the debate on their own.
The main outcome, major cardiovascular events, was not significantly reduced, which is an important limitation when judging the supplement as a general prevention tool. Many results came from secondary or subgroup analyses, which increases the chance that some findings occurred by chance. Some ranges of results were wide, meaning the true effect could be smaller or larger than the numbers suggest. The participants were mostly older U.S. adults, so the results may not apply equally to younger people, other countries, or people with specific medical conditions. The dose was one fixed amount of 1 gram per day, and the study did not test whether different doses or forms would change the results.
The Bottom Line
Confidence is high that daily omega-3 supplements do not meaningfully reduce major heart events or cancer in generally healthy adults, so routine use for general prevention is not supported. Confidence is moderate that they may reduce heart attacks and some heart procedures, based on the main trial data. Confidence is lower for the possible benefits on autoimmune disease and for the greater effects seen in subgroups, which need further study. Food sources such as fish remain a sensible choice for most people.
People who rarely eat fish, adults with several cardiovascular risk factors, and people with a history of heart problems may want to discuss omega-3 supplements with their doctor. Healthy adults who eat fish regularly are unlikely to gain much from adding a supplement based on these results. People taking blood-thinning medication or who have bleeding risks should check with a healthcare provider first, since high-dose omega-3s can affect bleeding.
The VITAL participants were followed for a median of about five years, so the results describe effects over that period. Any benefit for heart attacks likely develops gradually over years rather than weeks. People who try a supplement should not expect a quick change in blood tests or symptoms, and they should review progress with a doctor over the long term.
Frequently Asked Questions
Do omega-3 supplements prevent heart attacks?
Omega-3 supplements were linked to a 28% lower rate of total heart attacks in the VITAL trial of 25,871 U.S. adults followed for a median of 5.3 years. However, they did not significantly reduce major cardiovascular events overall, so experts do not routinely recommend them for healthy adults.
Can omega-3 fish oil reduce the risk of cancer?
Omega-3 supplements did not reduce total cancer incidence, specific cancer types, or overall death rates in the VITAL trial. The study followed about 25,871 adults for a median of 5.3 years, so the supplement does not appear to be an effective cancer prevention tool.
Who benefits most from taking omega-3 supplements?
People who eat little fish appeared to gain the most in the VITAL trial, along with Black participants and those with cardiovascular risk factors. These groups showed larger reductions in several heart outcomes, though subgroup findings are less certain and need confirmation in future studies.
How much omega-3 did the VITAL study give participants?
The VITAL trial gave participants 1 gram of marine omega-3 fatty acids per day, compared with a placebo pill. Outcomes were tracked over a median of 5.3 years to measure heart disease, cancer, autoimmune conditions, and deaths.
Want to Apply This Research?
- Log your weekly fish servings (for example, one serving equals about 3 ounces of cooked fish) and any daily omega-3 supplement doses in the app. Track whether you took the supplement each day as a simple yes or no check-in, and note the total weekly count so you can compare intake over time.
- Use the app to set a goal of eating fish, such as salmon, sardines, or trout, at least twice a week. If you rarely eat fish and are considering a supplement, flag this in your profile so the app can remind you to review the decision with your doctor at your next visit.
- Review your fish intake and supplement log monthly and look for patterns over three to six months. Pair these logs with routine checkups that include blood pressure, cholesterol, and heart health measures, and bring the data to your doctor. Reassess your supplement use at least once a year, especially if your diet, medications, or heart risk factors change.
This article summarizes a research study for general information only and is not medical advice. Omega-3 supplements can interact with medications, including blood thinners, and may affect bleeding risk. Talk with your doctor or another qualified healthcare provider before starting, stopping, or changing any supplement, especially if you have a heart condition, take prescription medicines, or have a medical question about your health.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.